Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tocopherol-modified therapeutic drug compounds

A drug compound, compound technology, applied in drug combination, sugar derivatives, organic chemistry, etc., can solve problems such as limited solubility

Inactive Publication Date: 2006-12-06
SONUS PHARM INC
View PDF3 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, while paclitaxel is soluble in alpha-tocopherol, other active moieties, including camptothecin and other taxanes, have limited solubility in alpha-tocopherol

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tocopherol-modified therapeutic drug compounds
  • Tocopherol-modified therapeutic drug compounds
  • Tocopherol-modified therapeutic drug compounds

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0129] Figure 5 The preparation of tocopheryl succinate 10-hydroxycamptothecin and tocopheryl succinate 7-ethyl-10-hydroxycamptothecin (SN38) is described. Tocopheryl succinate is converted to the corresponding acid chloride, which is then reacted with 10-hydroxycamptothecin or 7-ethyl-10-hydroxycamptothecin (SN38). The preparation of tocopheryl succinate 10-hydroxycamptothecin and tocopheryl succinate 7-ethyl-10-hydroxycamptothecin is described in Examples 2 and 3, respectively.

[0130] Figure 6 The preparation of 10,20-bis(tocopheryl succinate) SN38 containing one therapeutic drug (SN38) moiety, two tocopherol moieties and two linking moieties (succinyl groups) is described. The preparation of 10,20-bis(tocopheryl succinate) SN38 is described in Example 4.

[0131] Suitable linking moieties may include oligomers or polymers such as peptides, polypeptides, proteins, mono-, di- or polysaccharides, oligomers of ethylene glycol, poly(ethylene glycol), poly(alkylene oxide) ...

Embodiment 14

[0145] Example 14 compares the solubility of two representative tocopherol-modified camptothecin compounds of the invention and camptothecin in several media.

[0146] Further aspects of the invention provide emulsion, microemulsion and micellar formulations containing the compounds of the invention. Also provided are methods for making emulsion, microemulsion, and micellar formulations.

[0147] As used herein, the term "emulsion" refers to two immiscible liquids, such as a colloidal dispersion of oil and water in droplet form, each droplet generally being between 0.1 and 3.0 microns in diameter, unless the dispersed and continuous phases are Index-matched, emulsions are usually opaque. The limited stability of such systems, generally limited by the application or relative reference system, can be enhanced by the addition of amphiphilic molecules or viscosity enhancers.

[0148] The term "microemulsion" refers to a thermodynamically stable isotropic clear dispersion of two ...

Embodiment 15

[0156] Example 15 describes therapeutic drug compounds containing tocopherol modifications (e.g., tocopheryl succinate docetaxel, tocopheryl succinate paclitaxel, tocopheryl succinate camptothecin, tocopheryl succinate 7-beta A representative emulsion of tocopheryl-10-hydroxycamptothecin and tocopheryl succinate 10-hydroxycamptothecin). Example 16 describes the in vitro cytotoxicity of representative tocopherol-modified therapeutic drug compounds (eg, tocopheryl succinate 7-ethyl-10-hydroxycamptothecin and tocopheryl succinate camptothecin).

[0157] Further aspects of the invention provide micellar formulations comprising a compound of the invention and an aqueous phase. Micelles are organized aggregates of one or more surfactants in solution. In one embodiment, the compound is present in the formulation in an amount of about 0.005-3.0% by weight, based on the total weight of the formulation. In one embodiment, the compound is present in the formulation in an amount of abou...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
The average diameteraaaaaaaaaa
The average particle sizeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
Login to View More

Abstract

This invention provides tocopherol-modified therapeutic drug compounds; emulsion, microemulsion, and micelle formulations that include the compounds; methods for making the compounds and formulations; methods for administering the compounds and formulations; and methods for treating conditions using the compounds and formulations.

Description

technical field [0001] The present invention relates to novel therapeutic agents; compositions comprising the novel therapeutic agents; methods of administering and using these novel therapeutic agents and compositions. Background technique [0002] The ability to administer biologically effective drugs that are poorly soluble in biocompatible solvents to mammals is a major obstacle in the field of pharmaceutical and medicinal chemistry. Difficulties arise especially when the active drug is both insoluble in water and unstable in other biocompatible solvents. [0003] One way to solubilize agents is to chemically modify them or attach them to another molecule to alter their solubility characteristics in a particular solvent. Conjugates of active drugs, often referred to as prodrugs, include chemical derivatives of a biologically active parent compound that are converted to the parent compound in vivo. The active parent compound can be released fro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D491/22C07D407/12C07H15/252C07D311/72A61K9/107A61K31/337A61K31/355A61K31/4745A61P35/00
Inventor 张跃华L·C·戈尔德
Owner SONUS PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com